Investigation of the Relationship Between Salivary Histatine-5 Level and Vaginal Candidiasis in Women
1 other identifier
observational
90
1 country
1
Brief Summary
The low Histatine-5 (HST-5) level of the saliva can lead to vaginal candidiasis. Because HST-5 level in the saliva can effect vaginal Ph, flora and local defence mechanisms. Histatine-5 is secreted in the parotis and submandibular glands. İt riches histidine amino ascid and have antifungal activity. Salivary proteins and their plasma levels were found as similar in the literature.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 4, 2021
CompletedFirst Posted
Study publicly available on registry
September 14, 2021
CompletedStudy Start
First participant enrolled
October 21, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 6, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
March 6, 2022
CompletedMarch 8, 2022
March 1, 2022
5 months
September 4, 2021
March 6, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
SALIVARY HISTATINE-5 LEVEL IN THE WOMEN WITH VAGINAL CANDIDIASIS
we done salivary protein electrophoresis( as a small sample group ; consist of vaginal candidiasis and control patients) and Hst5 protein band was seen
1 month
Secondary Outcomes (1)
SALIVARY HISTATINE-5 LEVEL IN THE WOMEN WITH VAGINAL CANDIDIASIS
2 month
Study Arms (2)
Case group
vaginal candidiasis
Control group
healty women
Interventions
Eligibility Criteria
women with regularly menstrual cycle, diagnosed candidal vaginosis and not have any vaginal infection.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
İrem Şenyuva
Uşak, Turkey (Türkiye)
Related Publications (3)
Khurshid Z, Najeeb S, Mali M, Moin SF, Raza SQ, Zohaib S, Sefat F, Zafar MS. Histatin peptides: Pharmacological functions and their applications in dentistry. Saudi Pharm J. 2017 Jan;25(1):25-31. doi: 10.1016/j.jsps.2016.04.027. Epub 2016 May 4.
PMID: 28223859BACKGROUNDLoo JA, Yan W, Ramachandran P, Wong DT. Comparative human salivary and plasma proteomes. J Dent Res. 2010 Oct;89(10):1016-23. doi: 10.1177/0022034510380414. Epub 2010 Aug 25.
PMID: 20739693BACKGROUNDLiao H, Liu S, Wang H, Su H, Liu Z. Efficacy of Histatin5 in a murine model of vulvovaginal candidiasis caused by Candida albicans. Pathog Dis. 2017 Aug 31;75(6). doi: 10.1093/femspd/ftx072.
PMID: 28645176BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
İREM ŞENYUVA, M.D
USAK TRAINING AND RESEARCH HOSPITAL
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- M.D, Obstetrics and Gynecology
Study Record Dates
First Submitted
September 4, 2021
First Posted
September 14, 2021
Study Start
October 21, 2021
Primary Completion
March 6, 2022
Study Completion
March 6, 2022
Last Updated
March 8, 2022
Record last verified: 2022-03
Data Sharing
- IPD Sharing
- Will not share